IP Library Patent Application 11693993
Patent Application
App. No. 11/693,993

LARGE DOSE RIBAVIRIN FORMULATIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/693,993
Abstract

The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin.

Claims (27)

1 . A method for increasing patient compliance of a therapy comprising ribavirin, the method comprising administering a single pharmaceutical dosage form comprising 400 mg to 600 mg of ribavirin.

2 . The method of claim 1 , wherein the dosage form is a tablet which comprises 400 mg of ribavirin.

3 . The method of claim 1 , wherein the dosage form is a tablet which comprises 600 mg of ribavirin.

4 . The method of claim 1 , wherein the method is conducted two times per day.

5 . The method of claim 4 , wherein the method provides a daily dose of 800 mg, 1000 mg or 1200 mg of ribavirin.

6 . A method for increasing patient compliance of a therapy comprising ribavirin, the method comprising administering, twice a day to a subject, exactly one dosage form comprising 400 mg to 600 mg of ribavirin.

7 . The method of claim 6 , wherein the dosage form is a tablet which comprises 400 mg of ribavirin.

8 . The method of claim 7 , wherein the dosage form has at least one of the following characteristics:

a tablet hardness of from about 10.27 kp to about 12.88 kp;

a tablet weight of from about 0.5470 g to about 0.5535 g;

a tablet thickness of from about 4.86 mm to about 4.91 mm; and

a tablet friability of from about 0.23% to about 0.26%.

9 . The method of claim 6 , wherein the dosage form is a tablet which comprises 600 mg of ribavirin.

10 . The method of claim 9 , wherein the dosage form has at least one of the following characteristics:

a tablet hardness of from about 10.64 kp to about 12.58 kp;

a tablet weight of from about 0.8174 g to about 0.8357 g;

a tablet thickness of from about 6.38 mm to about 6.41 mm; and

a tablet friability of from about 0.23% to about 0.33%.

11 . The method of claim 6 , wherein the method provides a daily dose of 800 mg, 1000 mg or 1200 mg of ribavirin.

12 . The method according to claim 6 , wherein the dosage form is a tablet which is dispensed in HDPE bottles.

13 . The method according to claim 6 , wherein the dosage form is a tablet which is dispensed in a unit dose package.

14 . The method according to claim 13 , wherein the unit dose package is a blister pack containing 2, 4, 6, 8, 10, 12, 16, 20, 24, 48 or 56 tablets.

15 . A daily dosage regimen of ribavirin treatment comprising administering to a patient in need thereof exactly one dosage form of ribavirin and 8 hours to 16 hours later administering another one dosage form of ribavirin.

16 . The daily dosage regimen of claim 15 , wherein the dosage form comprises 400 mg to 600 mg of ribavirin.

17 . The daily dosage regimen of claim 16 , wherein the dosage form is a tablet which comprises 400 mg of ribavirin.

18 . The daily dosage regimen of claim 16 , wherein the dosage form is a tablet which comprises 600 mg of ribavirin.

19 . The daily dose regimen of claim 15 , wherein the regimen provides a daily dose of 800 mg, 1000 mg or 1200 mg of ribavirin.

Assignments (5)
SECURITY AGREEMENT Recorded Nov 23, 2011
From: KADMON PHARMACEUTICALS, LLC
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 027280/0954 →
RELEASE OF SECURITY INTEREST Recorded Jul 15, 2010
From: PNC BANK, NATIONAL ASSOCIATION
To: THREE RIVERS PHARMACEUTICALS, LLC; THREE RIVERS RESEARCH INSTITUTE I, LLC; 3RP INVESTMENT CORPORATION; THREE RIVERS BIOLOGICS, LLC; THREE RIVERS GLOBAL PHARMA, LLC
Reel/Frame 024686/0764 →
CHANGE OF ADDRESS Recorded May 20, 2010
From: THREE RIVERS PHARMACEUTICALS, LLC
To: THREE RIVERS PHARMACEUTICALS, LLC
Reel/Frame 024414/0922 →
SECURITY AGREEMENT Recorded Jan 15, 2008
From: THREE RIVERS PHARMACEUTICALS, LLC; THREE RIVERS RESEARCH INSTITUTE 1, LLC; 3RP INVESTMENT CORPORATION; THREE RIVERS BIOLOGICS, LLC; THREE RIVERS GLOBAL PHARMA, LLC
To: NATIONAL CITY BANK
Reel/Frame 020362/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2007
From: KERRISH, DONALD JOSEPH; DHANANTWARI, RAVINDRA
To: THREE RIVERS PHARMACEUTICALS, LLC
Reel/Frame 019726/0191 →